David A. Siegel Harmony Biosciences Holdings, Inc. Transaction History

Two Sigma Advisers, LP

$42.5 Billion
Q1 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 152,200 shares of HRMY stock, worth $4.59 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

152,200

Previous 152,700 0.33%

Holding current value

$4.59 Million

Previous $4.93 Million 3.61%

% of portfolio

0.01%

Previous 0.01%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$29.93 - $35.06 $14,965 - $17,530	-500 Reduced 0.33%	152,200 $5.11 Million
Q4 2023 Feb 14, 2024	SELL	$19.2 - $33.78 $2.68 Million - $4.71 Million	-139,400 Reduced 47.72%	152,700 $4.93 Million
Q3 2023 Nov 14, 2023	SELL	$31.89 - $39.03 $3.53 Million - $4.32 Million	-110,700 Reduced 27.48%	292,100 $9.57 Million
Q2 2023 Aug 14, 2023	BUY	$30.5 - $37.4 $1.19 Million - $1.45 Million	38,900 Added 10.69%	402,800 $14.2 Million
Q1 2023 May 15, 2023	SELL	$30.8 - $53.92 $1.74 Million - $3.05 Million	-56,600 Reduced 13.46%	363,900 $11.9 Million

Q4 2022 Feb 14, 2023	BUY	$45.4 - $60.91 $4.93 Million - $6.61 Million	108,600 Added 34.82%	420,500 $23.2 Million
Q3 2022 Nov 14, 2022	BUY	$42.06 - $55.45 $3.15 Million - $4.15 Million	74,900 Added 31.6%	311,900 $13.8 Million
Q2 2022 Aug 15, 2022	BUY	$33.54 - $52.15 $2.35 Million - $3.66 Million	70,200 Added 42.09%	237,000 $11.6 Million
Q1 2022 May 16, 2022	BUY	$33.14 - $51.13 $5.53 Million - $8.53 Million	166,800 New	166,800 $8.12 Million

Others Institutions Holding HRMY

# of Institutions

213

Shares Held

44M

Call Options Held

68.4K

Put Options Held

52.1K

View Full List

About Harmony Biosciences Holdings, Inc.

Ticker HRMY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,161,400
Market Cap $1.78B
Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...

More about HRMY

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account